NEW YORK (Reuters) - The enormous demand for weight-loss treatments like Novo Nordisk's Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said. More than half a dozen companies, from Pfizer Inc and Amgen Inc to smaller players like Altimmune Inc, are working on weight-loss therapies similar to Wegovy, viewing them as important future growth drivers. Novo was first to introduce an effective treatment shown to help people lose up to 15% of their weight. Eli Lilly and Co is expected to receive a U.S. weight loss approval for its similar drug, Mounjaro, later this year. | 06:22am
VIRGINIA BEACH, VA - The Breeden Company, the nationally recognized Virginia Beach based real estate development firm, announced today the promotion of two longtime Breeden associates to executive positions within the multifamily division. Jamie Kane, vice president of new development, and Christine Caldwell, vice president of third-party management, have both built strong track records driving revenue growth, stewardship and partnerships with owners, investors and community partners. The.